Physician profile
Gary Reznik
NPI 1043244296
$96,117.53
in general payments reported to CMS, 2019-2025
69 companies · $4,108 in 2025
The $4,108 reported for 2025 was more than what 91% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36K · 2020: $14K · 2021: $8,013 · 2022: $17K · 2023: $14K · 2024: $3,444 · 2025: $4,108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $10K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,915.03 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $45,452.90 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $29,576.23 | 2019-2023 | |
| Amgen INC. | $2,249.72 | 2019-2025 | Repatha, Evenity, Prolia |
| Novartis Pharmaceuticals Corporation | $1,380.68 | 2019-2025 | |
| Abbvie INC. | $1,373.98 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,089.99 | 2019-2025 | Farxiga, Brilinta, Breztri |
| Vifor Pharma, INC. | $1,003.88 | 2019-2025 | Veltassa |
| E.R. Squibb & Sons, L.L.C. | $841.06 | 2019-2025 | Camzyos, Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $805.64 | 2021-2025 | |
| Medtronic, INC. | $725.24 | 2022-2025 | Mycarelink, Micra, Aurora Ev-Icd Mri Surescan |
| Lilly USA, LLC | $711.10 | 2019-2025 | Taltz, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $699.54 | 2020-2025 | Trelegy Ellipta, Benlysta |
| Edwards Lifesciences Corporation | $656.23 | 2019-2025 | Sapien 3 Ultra Resilia |
| Ibsa Pharma INC. | $651.71 | 2021-2025 | Tirosint, Licart, Tirosint |
| Radius Health, INC. | $635.27 | 2021-2025 | Tymlos |
Show all 69 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Reznik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.